Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Rituximab Demonstrates Potential Efficacy in Treatment of Special Forms of RA
November 8th 2023A retrospective analysis suggested that administering rituximab to patients with rheumatoid arthritis complicated by lymphoma, systemic vasculitis, or extra-articular lesions was associated with improved outcomes.
Read More
What We’re Reading: Free HIV Medication; MA Anticompetitive Regulations; Surge in Syphilis Cases
November 8th 2023Medicare may cover full cost of preexposure prophylaxis drugs; rules aim to prevent excessive compensation in Medicare Advantage (MA) market; health officials advocate for widespread syphilis testing and intervention.
Read More
Myasthenia Gravis Potential Result of Cancer Treatment
November 8th 2023When patients are undergoing treatment for cancer, clinicians should be aware of the potential to develop myasthenia gravis from immune checkpoint inhibitors (ICI), new research stresses, with ongoing surveillance and risk factor identification becoming necessary steps.
Read More
Accelerated Aging Associated With COPD, Impaired Lung Function
November 7th 2023High levels of phenotypic age acceleration (PhenoAgeAccel) were found to have a more significant effect on lung function in patients with chronic obstructive pulmonary disease (COPD), older patients, and White patients.
Read More
What We’re Reading: AI Heart Attack Detection; FDA Menthol Ban; Shooting Survivor Care Obstacles
November 7th 2023Artificial intelligence (AI) could help detect heart attack risk signs and prevent sudden cardiac death; Advocates demand the Biden administration finalize the proposed FDA ban on menthol cigarettes; Gun violence survivors and their families have many ongoing medical needs.
Read More
Rhenium Obisbemeda for Breast Cancer, Leptomeningeal Metastases Receives ODD From FDA
November 6th 2023Rhenium (186Re) obisbemeda (Plus Therapeutics) shows potential to address the unmet need of new treatment options for patients with breast cancer and leptomeningeal metastases and will continue to be evaluated in the ReSPECT-LM program. The orphan drug designation (ODD) was granted on November 3.
Read More
Rates of Elevated LDL-C Have Decreased, but Awareness, Treatment Still Suboptimal
November 6th 2023The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant consideration of pharmacotherapy, and 1 in 48 had high levels of LDL-C that are indicated for medication.
Read More
Contributor: How Patients and Caregivers Can Be a Catalyst for Rare Disease Innovation
November 5th 2023Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.
Read More
Multiple Barriers Impact Kidney Care Disparities in LGBTQ+ Individuals
November 5th 2023Presenters at American Society of Nephrology Kidney Week 2023 highlighted the importance of understanding the barriers faced by the LGBTQ+ community that impact kidney outcomes and the need to gather better data for studying these issues.
Read More
Wide Variation Seen in County-Level Breast Cancer Mortality Linked to SDOH
November 4th 2023Data from 2176 US counties link obesity and higher breast cancer mortality, while also showing varying degrees of association between mortality and access to healthy lifestyle options per social determinants of health (SDOH).
Read More
Prediction Model Effective for Community-Acquired Pneumonia in Those With Acute Asthma Exacerbations
November 4th 2023This newly developed prediction model evaluating community-acquired pneumonia risk was noted to demonstrate accuracy, strong discriminatory qualities, and practicability in clinical settings.
Read More
Economic Burden and Predicting Disease Progression of CKD Highlighted at ASN Kidney Week 2023
November 4th 2023Posters at ASN Kidney Week 2023 explored the economic burden brought on by chronic kidney disease (CKD) and further validated the Klinrisk model’s ability to predict progressive forms of CKD.
Read More
A Bioartificial Kidney Would Reduce Transplant Wait Times, Costs for Patients on Dialysis
November 4th 2023The use of a bioartificial kidney could save the transplant population from a life of immunosuppression drugs and save costs, according to Shuvo Roy, PhD, professor of bioengineering at the University of California San Francisco.
Read More